ライフサイエンスコーパス: had a serious adverse event

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します

1 ts were reported in 36 (46%) of 78 patients and eight (10%) had a serious adverse event judged to be treatment related.

2 tients in the R-CVP group had an adverse event and 63 [20%] had a serious adverse event).

3 In total, 22 of 205 patients (10.7%) had a serious adverse event in the vasopressin group vs 17 of

4 Four participants (8%) had a serious adverse event, one of which (intermediate uveit

5 An infant in group A had a serious adverse event other than death (injection absce

6 vacizumab group, 130 (42%) of 313 patients with safety data had a serious adverse event, compared with 114 (36%) controls

7 One patient in group five had a serious adverse event of anaemia, thought to be related

8 to-face group, and 20 (8%) patients in the usual care group had a serious adverse event.

9 trafiltration group than in the pharmacologic-therapy group had a serious adverse event (72% vs. 57%, P=0.03).

10 One patient (in T group) had a serious adverse event (considered unrelated to telaprev

11 No patient had a serious adverse event related to the study drug.

12 No patient had a serious adverse event related to the study drug.

13 One patient had a serious adverse event, worsening depression, which we j

14 16 (9%) of 184 patients had a serious adverse event related to treatment with aveluma

15 Across both trials, 38 (20%) patients had a serious adverse event during the first 48 weeks and 44

16 19 (8%) of 249 patients had a serious adverse event related to treatment with aveluma

17 CVP group had an adverse event and 71 [23%] of 312 patients had a serious adverse event; 288 [91%] of 315 patients in the

18 Four (33%) patients had a serious adverse event, and 12 (100%) patients had treat

19 Four of 73 (5.5%) patients had a serious adverse event in the placebo group, ten of 71 (

20 d of 26 months (interquartile range, 20-30 mo), no patients had a serious adverse event or relapse of vasculitis.

21 allocated ramucirumab and 54 (20%) of 265 assigned placebo had a serious adverse event that was judged by the investigat

22 40 (42%) participants who received platelet transfusion had a serious adverse event during their hospital stay, as di

23 Four patients assigned the vaccine had a serious adverse event, which was unrelated to the vacci

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。